These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Nguyen VN; Mirejovský T; Melinová L; Mandys V Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866 [TBL] [Abstract][Full Text] [Related]
4. Pathological Implications of Mucin Signaling in Metastasis. Dhanisha SS; Guruvayoorappan C Curr Cancer Drug Targets; 2023; 23(8):585-602. PubMed ID: 36941808 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of the mechanism and treatment significance of Mucins in lung cancer. Ning Y; Zheng H; Zhan Y; Liu S; Yang Y; Zang H; Luo J; Wen Q; Fan S J Exp Clin Cancer Res; 2020 Aug; 39(1):162. PubMed ID: 32807223 [TBL] [Abstract][Full Text] [Related]
6. Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer. Yu CJ; Shun CT; Yang PC; Lee YC; Shew JY; Kuo SH; Luh KT Am J Respir Crit Care Med; 1997 Apr; 155(4):1419-27. PubMed ID: 9105088 [TBL] [Abstract][Full Text] [Related]
7. The impact of intracytoplasmic mucin in lung adenocarcinoma with pneumonic radiological presentation. Duruisseaux M; Antoine M; Rabbe N; Poulot V; Fleury-Feith J; Vieira T; Lavolé A; Cadranel J; Wislez M Lung Cancer; 2014 Mar; 83(3):334-40. PubMed ID: 24461303 [TBL] [Abstract][Full Text] [Related]
8. MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer. Chen CH; Wang SW; Chen CW; Huang MR; Hung JS; Huang HC; Lin HH; Chen RJ; Shyu MK; Huang MC Gynecol Oncol; 2013 Mar; 128(3):560-7. PubMed ID: 23262208 [TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Singh AP; Chauhan SC; Bafna S; Johansson SL; Smith LM; Moniaux N; Lin MF; Batra SK Prostate; 2006 Mar; 66(4):421-9. PubMed ID: 16302265 [TBL] [Abstract][Full Text] [Related]
10. Correlation between mucin biology and tumor heterogeneity in lung cancer. Xu M; Wang DC; Wang X; Zhang Y Semin Cell Dev Biol; 2017 Apr; 64():73-78. PubMed ID: 27569189 [TBL] [Abstract][Full Text] [Related]
11. The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers. Jonckheere N; Van Seuningen I Biochimie; 2010 Jan; 92(1):1-11. PubMed ID: 19818375 [TBL] [Abstract][Full Text] [Related]
12. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. Arai T; Fujita K; Fujime M; Irimura T Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558 [TBL] [Abstract][Full Text] [Related]
13. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. Dong Y; Walsh MD; Cummings MC; Wright RG; Khoo SK; Parsons PG; McGuckin MA J Pathol; 1997 Nov; 183(3):311-7. PubMed ID: 9422987 [TBL] [Abstract][Full Text] [Related]
14. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. Yonezawa S; Nakamura A; Horinouchi M; Sato E J Hepatobiliary Pancreat Surg; 2002; 9(3):328-41. PubMed ID: 12353144 [TBL] [Abstract][Full Text] [Related]
15. Expression of targeting protein for xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer. Ma Y; Lin D; Sun W; Xiao T; Yuan J; Han N; Guo S; Feng X; Su K; Mao Y; Cheng S; Gao Y Clin Cancer Res; 2006 Feb; 12(4):1121-7. PubMed ID: 16489064 [TBL] [Abstract][Full Text] [Related]
16. Combined evaluation of mucin antigen and E-cadherin expression may help select patients with gastric cancer suitable for minimally invasive therapy. Tanaka M; Kitajima Y; Sato S; Miyazaki K Br J Surg; 2003 Jan; 90(1):95-101. PubMed ID: 12520583 [TBL] [Abstract][Full Text] [Related]
17. Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Utsunomiya T; Yonezawa S; Sakamoto H; Kitamura H; Hokita S; Aiko T; Tanaka S; Irimura T; Kim YS; Sato E Clin Cancer Res; 1998 Nov; 4(11):2605-14. PubMed ID: 9829723 [TBL] [Abstract][Full Text] [Related]
18. Mucins as immunogenic targets in cancer. Syrigos KN; Karayiannakis AJ; Zbar A Anticancer Res; 1999; 19(6B):5239-44. PubMed ID: 10697542 [TBL] [Abstract][Full Text] [Related]
19. Mucins in pancreatic cancer and its microenvironment. Kaur S; Kumar S; Momi N; Sasson AR; Batra SK Nat Rev Gastroenterol Hepatol; 2013 Oct; 10(10):607-20. PubMed ID: 23856888 [TBL] [Abstract][Full Text] [Related]
20. Mucins and CD56 as markers of tumour invasion and prognosis in periampullary cancer. Aloysius MM; Zaitoun AM; Awad S; Ilyas M; Rowlands BJ; Lobo DN Br J Surg; 2010 Aug; 97(8):1269-78. PubMed ID: 20602499 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]